Eylea (aflibercept) Injection

For the treatment of wet AMD

Treatment with EYLEA® (aflibercept) Injection

Wet AMD eye with excessive VEGF

Wet AMD eye being treated with EYLEA® (aflibercept) Injection


Wet AMD eye with excessive VEGF Wet AMD eye with treatment
EYLEA

EYLEA is a prescription medicine that has been approved by the FDA for the treatment of patients with wet AMD. EYLEA is the result of nearly a decade of scientific research and development. EYLEA has been designed to bind to VEGF.

Treatment with EYLEA is recommended to be administered once every 2 months (8 weeks) following 3 initial monthly (4 weeks) injections. EYLEA may be administered as frequently as once every 4 weeks, though additional efficacy was not observed when EYLEA was dosed every 4 weeks compared to every 8 weeks.

In two well-controlled clinical studies of over 2400 patients with wet AMD this treatment frequency was shown to maintain* or improve vision over one year in more than 9 out of 10 patients.

*Defined as losing fewer than 15 letters based on best-corrected visual acuity on an ETDRS eye chart.

Your doctor will talk with you about your specific dosing schedule.

EYLEA is injected into the eye. You should not receive EYLEA if you have an infection in or around the eye, eye pain or redness (active intraocular inflammation), or known allergies to any of the ingredients of EYLEA, including aflibercept. The most common side effects that occurred during these clinical trials in patients receiving EYLEA included bloodshot eye (conjunctival hemorrhage), eye pain, moving spots in the field of vision (vitreous floaters), or flashes of light, which may or may not be related to detachment of the vitreous (the gel-like substance inside the eye) from the retina (vitreous detachment).

IMPORTANT PRESCRIBING INFORMATION FOR EYLEA® (aflibercept) INJECTION

EYLEA® (aflibercept) Injection is a prescription medicine approved for the treatment of patients with wet AMD. The recommended dose for EYLEA is 2 mg administered by injection in the eye every 2 months (8 weeks) following 3 initial monthly (4 weeks) injections. EYLEA may be dosed once per month, but additional benefit was not seen with this dosing plan.

IMPORTANT SAFETY INFORMATION FOR EYLEA® (aflibercept) INJECTION

EYLEA® (aflibercept) Injection is a prescription medication administered by injection into the eye. You should not use EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept. As with all medications, EYLEA can cause side effects.

Injection into the eye can result in an infection in the eye and retinal detachment. Inflammation in the eye has been reported with the use of EYLEA.

In some patients, injections with EYLEA may trigger a temporary increase in eye pressure within 1 hour of the injection. Sustained increases in eye pressure have been reported with repeated injections, and your doctor may monitor this after each injection.

There is a potential risk of serious and sometimes fatal side effects related to blood clots, leading to heart attack or stroke in patients receiving EYLEA.

The most common side effects reported in patients receiving EYLEA are increased redness in the eye, eye pain, cataract, moving spots in the field of vision, increased pressure in the eye, and vitreous (gel-like substance) detachment.

Serious side effects related to the injection procedure are rare but can occur including infection inside the eye, retinal detachment, cataract, increased pressure in the eye, and vitreous detachment.

It is important that you contact your doctor right away if you think you might be experiencing any side effects.

EYLEA is for prescription use only. For additional safety information, please talk to your doctor and see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call1-800-FDA-1088.

To view the publication, you will be directed to a third-party site that is not owned or controlled by Regeneron Pharmaceuticals, Inc. This link is provided as a resource to the viewer. The use of third-party web sites is at your own risk, and is subject to the terms and conditions of such sites.

Cancel